Czech Republic Pharmaceutical Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 5.06 Billion |
| Market Size (2029) | USD 6.86 Billion |
| CAGR (2024 - 2029) | 6.25 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Czech Republic Pharmaceutical Market Analysis
The Czech Republic Pharmaceutical Market size is estimated at USD 5.06 billion in 2024, and is expected to reach USD 6.86 billion by 2029, growing at a CAGR of 6.25% during the forecast period (2024-2029).
The Czech pharmaceutical market is likely to be influenced by favorable government scenarios, the active involvement of government organizations to ensure the availability of pharmaceutical drugs in the country, and rising healthcare expenditures.
The recent changes in medicine price setting in the Czech Republic are projected to drive pharmaceutical market growth in the country during the forecast period. For instance, in May 2024, the Czech government proposed changes in setting medicine prices to ensure that reimbursement rates reflect the most current and realistic market conditions. This is projected to lead to more competitive pricing and increased availability of various drugs in the country, thereby driving market growth.
In addition, the Czech government is actively ensuring the availability of pharmaceutical drugs in the country through legislative changes, which are set to drive market growth during the forecast period. For instance, in January 2024, the pharmaceutical industry in the Czech Republic was impacted by a complex amendment to the Medicinal Products Act No. 378/2007 Coll. to ensure the availability of medicinal products for human use in the event of interruption or termination of their supply to the market. The amendment introduced a "limited availability" label for certain medicinal products. It imposed obligations on marketing authorization holders, distributors, and pharmacy operators, which could lead to improved access to essential medicines, thereby increasing demand and driving market growth.
Thus, the above-mentioned legislative changes are expected to enhance the availability and affordability of medicinal products, driving the growth of the market studied.
Furthermore, substantial investments in the healthcare industry, the significant healthcare workforce, and the well-equipped healthcare system in the Czech Republic may drive the growth of the pharmaceutical market in the future. For instance, according to the data accessed from the OECD in May 2024, the Czech Republic spends USD 4,512 per capita on health, similar to the OECD average of USD 4,986, which is equal to 9.1% of GDP. The same source shows around 4.3 practicing doctors per 1,000 population and 9.0 practicing nurses. The Czech Republic has 6.7 hospital beds per 1,000 population, more than the OECD average of 4.3.
Thus, the above-mentioned factors are projected to drive the growth of the Czech pharmaceutical market during the forecast period. However, the rise of generic medications may restrain the market growth.
Czech Republic Pharmaceutical Market Trends
The Anti-diabetic Segment is Expected to Register Significant Growth During the Forecast Period
The Czech Republic faces a growing diabetes burden, which is estimated to drive the demand for pharmaceutical drugs for the treatment and management of diabetes in the country. For instance, according to the data accessed from the IDF in May 2024, around 791.4 thousand people suffered from diabetes in 2021, and the number is estimated to increase to 799.2 thousand by 2030 and 827.9 thousand by the end of 2045.
The active participation of government organizations in the country in eradicating diabetes is projected to drive market growth significantly during the forecast period. For instance, in March 2023, the Czech Ministry of Health published the Applied Health Research Support Program for 2024-2030. As per the program, in the coming few years, health research on diabetes prevention will primarily focus on the screening for diabetic retinopathy with a high focus on personalized medicine, enabling the detection of predictors of type 2 diabetes treatment. Thus, public health initiatives and educational programs are raising awareness about diabetes risk factors and symptoms in the Czech Republic. This is set to lead to earlier diagnoses and prompt treatment initiation, driving the use of anti-diabetic drugs.
Moreover, the Czech government plays a substantial role by reimbursing the costs of some diabetes medications. This financial support makes treatment more accessible and influences the overall market size of the anti-diabetic segment. For instance, in August 2022, the Czech Republic implemented a new reimbursement program for innovative diabetes medications, demonstrating the government's commitment to supporting access to these therapies.
Therefore, factors such as the rising prevalence of diabetes and the active participation of government organizations in the eradication of diabetes from the country are projected to drive the demand for anti-diabetes drugs during the study period.
The Branded Drugs Segment is Expected to Register Fastest Growth During the Forecast Period
The branded drugs segment in the market studied is expected to experience significant growth due to the demand for innovation, marketing efforts, the reference pricing system, and patient preferences in the country.
The rising prevalence of various chronic diseases in the country is projected to accelerate the market growth during the forecast period. For instance, according to the Czech National Cancer Control Plan 2030 report, published by the Ministry of Health in June 2022, approximately 60,000 malignant tumor cases (excluding other skin tumor cases) are diagnosed in the Czech Republic every year. As per the same source, the overall prevalence of people with a history of cancer is more than 700,000. Also, every third citizen of the Czech Republic is expected to develop some cancer during their lifetime, and by 2030, the cancer prevalence is projected to exceed 750,000 people. Thus, the high prevalence of cancer in the country is projected to accelerate the demand for branded drugs during the forecast period.
Furthermore, the country's rising number of drug approvals is also expected to drive market growth during the forecast period. For instance, in January 2023, the European Commission approved a revolutionary prostate cancer drug, XTANDI (enzalutamide), for use in additional recurrent early prostate cancer treatment settings. This drug is one of the first novel hormone therapies available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union. Thus, such approvals are projected to increase demand for cancer drugs, driving segment growth.
Therefore, factors such as the rising prevalence of chronic diseases and surging drug approvals are projected to drive the growth of the branded drugs segment during the forecast period.
Czech Republic Pharmaceutical Industry Overview
The Czech pharmaceutical market is highly competitive and has several major players. In terms of market share, few of the major players are currently dominating the market. Key companies that are currently dominating the market include Abbvie Inc., Merck & Co. Inc., Amgen Inc., Pfizer Inc., and GlaxoSmithKline PLC.
Czech Republic Pharmaceutical Market Leaders
-
Abbvie Inc.
-
Merck & Co., Inc.
-
Novartis International AG
-
Pfizer Inc.
-
Sanofi S.A.
*Disclaimer: Major Players sorted in no particular order
Czech Republic Pharmaceutical Market News
- October 2023: Motagon Cannabis (Motagon), a subsidiary of HEATON Group AS (Heaton), completed its import of medical cannabis flower to Prague, Czechia, after receiving approval from Czechia’s State Institute for Drug Control (SUKL) and the Ministry of Health.
- June 2023: The Masaryk University received the building permit for a biopharma hub in the Czech Republic worth CZK 2.5 billion (USD 0.1 billion), which is likely to lead to increased production and research capabilities, which could, in turn, lead to the development of new and innovative medicinal products.
Czech Republic Pharmaceutical Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions & Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
-
4.1 Market Overview
- 4.1.1 Healthcare Expenditure (Govt. Vs Private)
- 4.1.2 Pharmaceutical Imports and Exports
- 4.1.3 Epidemiology Data for Key Diseases
- 4.1.4 Regulatory Landscape/Regulatory Bodies
- 4.1.5 Licensing and Market Authorization (For both Local Production and Imported Goods)
- 4.1.6 Pipeline Analysis
- 4.1.6.1 By Phase
- 4.1.6.2 By Sponsor
- 4.1.6.3 By Disease
- 4.1.7 Statically Overview
- 4.1.7.1 Number of Hospitals
- 4.1.7.2 Employment in the Pharmaceutical Sector
- 4.1.7.3 R&D Expenditure
- 4.1.8 Ease of Doing Business
-
4.2 Market Drivers
- 4.2.1 Rising Healthcare Expenditure
- 4.2.2 Rising Incidence of Chronic Disease
-
4.3 Market Restraints
- 4.3.1 Stringent Regulatory Scenario
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Therapeutic Category
- 5.1.1 Anti-infectives
- 5.1.2 Cardiovascular
- 5.1.3 Gastrointestinal
- 5.1.4 Anti-diabetic
- 5.1.5 Respiratory
- 5.1.6 Dermatologicals
- 5.1.7 Musculoskeletal System
- 5.1.8 Nervous System
- 5.1.9 Other Therapeutic Categories
-
5.2 By Drug Type
- 5.2.1 Prescription Drug
- 5.2.1.1 Branded Drugs
- 5.2.1.2 Generic Drugs
- 5.2.2 OTC Drugs
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc.
- 6.1.2 Merck & Co. Inc.
- 6.1.3 Novartis International AG
- 6.1.4 Pfizer Inc.
- 6.1.5 Sanofi SA
- 6.1.6 F. Hoffmann-La Roche AG
- 6.1.7 AstraZeneca PLC
- 6.1.8 Eli Lilly and Company
- 6.1.9 Novartis International AG
- 6.1.10 GlaxoSmithKline PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityCzech Republic Pharmaceutical Industry Segmentation
As per the scope of this report, pharmaceuticals are referred to as prescribed and non-prescription drugs. These medicines can be bought by an individual with or without a doctor's prescription and are consumed to treat various diseases. The report also covers the in-depth analysis of qualitative and quantitative data.
The Czech pharmaceutical market is segmented by therapeutic category and drug type. By therapeutic category, the market is segmented into anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, respiratory, dermatological, musculoskeletal system, nervous system, and other therapeutic categories. By drug type, the market is segmented into prescription drugs and OTC drugs. By prescription drugs, the market is segmented into branded drugs and generic drugs. For each segment, the market size and forecast are provided in terms of value (USD).
| By Therapeutic Category | Anti-infectives | |
| Cardiovascular | ||
| Gastrointestinal | ||
| Anti-diabetic | ||
| Respiratory | ||
| Dermatologicals | ||
| Musculoskeletal System | ||
| Nervous System | ||
| Other Therapeutic Categories | ||
| By Drug Type | Prescription Drug | Branded Drugs |
| Generic Drugs | ||
| By Drug Type | OTC Drugs |
Czech Republic Pharmaceutical Market Research FAQs
How big is the Czech Republic Pharmaceutical Market?
The Czech Republic Pharmaceutical Market size is expected to reach USD 5.06 billion in 2024 and grow at a CAGR of 6.25% to reach USD 6.86 billion by 2029.
What is the current Czech Republic Pharmaceutical Market size?
In 2024, the Czech Republic Pharmaceutical Market size is expected to reach USD 5.06 billion.
Who are the key players in Czech Republic Pharmaceutical Market?
Abbvie Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc. and Sanofi S.A. are the major companies operating in the Czech Republic Pharmaceutical Market.
What years does this Czech Republic Pharmaceutical Market cover, and what was the market size in 2023?
In 2023, the Czech Republic Pharmaceutical Market size was estimated at USD 4.74 billion. The report covers the Czech Republic Pharmaceutical Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Czech Republic Pharmaceutical Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Czech Republic Pharmaceutical Industry Report
Statistics for the 2024 Czech Republic Pharmaceutical market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Czech Republic Pharmaceutical analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
